Boston Scientific today shared new clinical data supporting multiple therapies at the Heart Rhythm Society (HRS) 2025 Meeting ...

Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a ...

Elutia Inc. has announced the launch of a clinical study for EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs).

Atrial fibrillation is the most common chronic arrhythmia. It is characterized by erratic atrial electrical activity with atrial rates of 400 to 600 beats per minute. The P wave is absent on the ...

This marks the latest recall-related issue for HeartMate in recent years. Last June, the FDA deemed another recall as serious ...

Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers ... We remain bullish on the Watchman left atrial appendage closure franchise (despite ...

Introduction: Shoulder pain and disability ipsilateral to the implant site is a common complication of cardiac rhythm device implantation, yet very little has been published about this morbidity.

Tim Boreham sharpens his knifes to look under the hood at cardiac pacing device innovator EBR Systems after its US FDA approval. This month, the FDA approved Artrya's (ASX:AYA) arterial plaque ...